Hydroxocobalamin

Anemia, Pernicious, Fractures, Multiple, Vitamin B complex deficiency + 11 more

Treatment

3 FDA approvals

20 Active Studies for Hydroxocobalamin

What is Hydroxocobalamin

Hydroxocobalamin

The Generic name of this drug

Treatment Summary

Hydroxocobalamin is an injectable form of vitamin B12 used to treat a vitamin B12 deficiency. It can also be used to treat cyanide poisoning, Leber's optic atrophy, and toxic amblyopia. The drug is also known as vitamin B12a and hydroxycobalamin.

Cyanokit

is the brand name

image of different drug pills on a surface

Hydroxocobalamin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Cyanokit

Hydroxocobalamin

2007

7

Approved as Treatment by the FDA

Hydroxocobalamin, also known as Cyanokit, is approved by the FDA for 3 uses like Vitamin B12 Deficiency and Schilling Test .

Vitamin B12 Deficiency

Schilling Test

Vitamin B 12 Deficiency

Effectiveness

How Hydroxocobalamin Affects Patients

Hydroxocobalamin is a form of Vitamin B12 that is given as an injection. Vitamin B12 and a related vitamin (methylcobalamin) both play a role in several biological processes. Low levels of this vitamin can cause problems with nerve cells and the production of lipoprotein. It also affects how folic acid is processed in the body, which can interfere with cell maturation. Vitamin B12 is important for growth, how cells replicate, how blood is made, and how proteins are made. It also helps to break down fats, carbohydrates, and proteins.

How Hydroxocobalamin works in the body

Vitamin B12 has four forms: deoxyadenosylcobalamin, methylcobalamin, hydroxocobalamin, and cyanocobalamin. The body mainly uses two of these forms, methylcobalamin and 5-deoxyadenosyl cobalamin. Methylcobalamin helps the body to convert the amino acid homocysteine into methionine. Methionine is important for DNA methylation. 5-Deoxyadenosyl cobalamin helps with the conversion of L-methylmalonyl-CoA to succinyl-CoA. This conversion helps the body get energy

When to interrupt dosage

The proposed dosage of Hydroxocobalamin is contingent upon the diagnosed affliction, such as Neurodegenerative Diseases, Fractures, Multiple and Anger Management Therapy. The sum of dosage diversifies, depending on the approach of administration (e.g. Injection, powder, lyophilized, for solution - Intravenous or Tablet, chewable) highlighted in the table beneath.

Condition

Dosage

Administration

Vitamin B 12 Deficiency

, 25.0 mg/mL, 2500.0 mg, 1.0 mg/mL, 5000.0 mg, 50.0 mg/mL, 0.006 mg, 0.015 mg, 0.00522 mg

, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular, Liquid, Liquid - Intramuscular, Powder, for solution, Powder, for solution - Intravenous, Injection, solution, Injection, solution - Intramuscular, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Tablet, chewable - Oral, Tablet, chewable, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Fractures, Multiple

, 25.0 mg/mL, 2500.0 mg, 1.0 mg/mL, 5000.0 mg, 50.0 mg/mL, 0.006 mg, 0.015 mg, 0.00522 mg

, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular, Liquid, Liquid - Intramuscular, Powder, for solution, Powder, for solution - Intravenous, Injection, solution, Injection, solution - Intramuscular, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Tablet, chewable - Oral, Tablet, chewable, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Vitamin B complex deficiency

, 25.0 mg/mL, 2500.0 mg, 1.0 mg/mL, 5000.0 mg, 50.0 mg/mL, 0.006 mg, 0.015 mg, 0.00522 mg

, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular, Liquid, Liquid - Intramuscular, Powder, for solution, Powder, for solution - Intravenous, Injection, solution, Injection, solution - Intramuscular, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Tablet, chewable - Oral, Tablet, chewable, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Paralysis

, 25.0 mg/mL, 2500.0 mg, 1.0 mg/mL, 5000.0 mg, 50.0 mg/mL, 0.006 mg, 0.015 mg, 0.00522 mg

, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular, Liquid, Liquid - Intramuscular, Powder, for solution, Powder, for solution - Intravenous, Injection, solution, Injection, solution - Intramuscular, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Tablet, chewable - Oral, Tablet, chewable, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Toxic effect of hydrocyanic acid and cyanides

, 25.0 mg/mL, 2500.0 mg, 1.0 mg/mL, 5000.0 mg, 50.0 mg/mL, 0.006 mg, 0.015 mg, 0.00522 mg

, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular, Liquid, Liquid - Intramuscular, Powder, for solution, Powder, for solution - Intravenous, Injection, solution, Injection, solution - Intramuscular, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Tablet, chewable - Oral, Tablet, chewable, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Schilling Test

, 25.0 mg/mL, 2500.0 mg, 1.0 mg/mL, 5000.0 mg, 50.0 mg/mL, 0.006 mg, 0.015 mg, 0.00522 mg

, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular, Liquid, Liquid - Intramuscular, Powder, for solution, Powder, for solution - Intravenous, Injection, solution, Injection, solution - Intramuscular, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Tablet, chewable - Oral, Tablet, chewable, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Neurological Disorders

, 25.0 mg/mL, 2500.0 mg, 1.0 mg/mL, 5000.0 mg, 50.0 mg/mL, 0.006 mg, 0.015 mg, 0.00522 mg

, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular, Liquid, Liquid - Intramuscular, Powder, for solution, Powder, for solution - Intravenous, Injection, solution, Injection, solution - Intramuscular, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Tablet, chewable - Oral, Tablet, chewable, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Behavior Disorders

, 25.0 mg/mL, 2500.0 mg, 1.0 mg/mL, 5000.0 mg, 50.0 mg/mL, 0.006 mg, 0.015 mg, 0.00522 mg

, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular, Liquid, Liquid - Intramuscular, Powder, for solution, Powder, for solution - Intravenous, Injection, solution, Injection, solution - Intramuscular, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Tablet, chewable - Oral, Tablet, chewable, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Burn Patients

, 25.0 mg/mL, 2500.0 mg, 1.0 mg/mL, 5000.0 mg, 50.0 mg/mL, 0.006 mg, 0.015 mg, 0.00522 mg

, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular, Liquid, Liquid - Intramuscular, Powder, for solution, Powder, for solution - Intravenous, Injection, solution, Injection, solution - Intramuscular, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Tablet, chewable - Oral, Tablet, chewable, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Therapeutic Agent Toxicity

, 25.0 mg/mL, 2500.0 mg, 1.0 mg/mL, 5000.0 mg, 50.0 mg/mL, 0.006 mg, 0.015 mg, 0.00522 mg

, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular, Liquid, Liquid - Intramuscular, Powder, for solution, Powder, for solution - Intravenous, Injection, solution, Injection, solution - Intramuscular, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Tablet, chewable - Oral, Tablet, chewable, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Anger Management Therapy

, 25.0 mg/mL, 2500.0 mg, 1.0 mg/mL, 5000.0 mg, 50.0 mg/mL, 0.006 mg, 0.015 mg, 0.00522 mg

, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular, Liquid, Liquid - Intramuscular, Powder, for solution, Powder, for solution - Intravenous, Injection, solution, Injection, solution - Intramuscular, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Tablet, chewable - Oral, Tablet, chewable, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Iron Deficiency Anemia

, 25.0 mg/mL, 2500.0 mg, 1.0 mg/mL, 5000.0 mg, 50.0 mg/mL, 0.006 mg, 0.015 mg, 0.00522 mg

, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular, Liquid, Liquid - Intramuscular, Powder, for solution, Powder, for solution - Intravenous, Injection, solution, Injection, solution - Intramuscular, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Tablet, chewable - Oral, Tablet, chewable, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Anemia, Pernicious

, 25.0 mg/mL, 2500.0 mg, 1.0 mg/mL, 5000.0 mg, 50.0 mg/mL, 0.006 mg, 0.015 mg, 0.00522 mg

, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular, Liquid, Liquid - Intramuscular, Powder, for solution, Powder, for solution - Intravenous, Injection, solution, Injection, solution - Intramuscular, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Tablet, chewable - Oral, Tablet, chewable, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

prophylaxis of Vitamin B12 deficiency

, 25.0 mg/mL, 2500.0 mg, 1.0 mg/mL, 5000.0 mg, 50.0 mg/mL, 0.006 mg, 0.015 mg, 0.00522 mg

, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular, Liquid, Liquid - Intramuscular, Powder, for solution, Powder, for solution - Intravenous, Injection, solution, Injection, solution - Intramuscular, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Tablet, chewable - Oral, Tablet, chewable, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Warnings

There are 20 known major drug interactions with Hydroxocobalamin.

Common Hydroxocobalamin Drug Interactions

Drug Name

Risk Level

Description

Abacavir

Minor

Hydroxocobalamin may decrease the excretion rate of Abacavir which could result in a higher serum level.

Acetaminophen

Minor

Hydroxocobalamin may decrease the excretion rate of Acetaminophen which could result in a higher serum level.

Aclidinium

Minor

Hydroxocobalamin may decrease the excretion rate of Aclidinium which could result in a higher serum level.

Acrivastine

Minor

Hydroxocobalamin may decrease the excretion rate of Acrivastine which could result in a higher serum level.

Albutrepenonacog alfa

Minor

Hydroxocobalamin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.

image of a doctor in a lab doing drug, clinical research

Hydroxocobalamin Novel Uses: Which Conditions Have a Clinical Trial Featuring Hydroxocobalamin?

202 active clinical trials are currently being conducted to evaluate the potential of Hydroxocobalamin in the management of Iron Deficiency Anemia, Vitamin B12 Deficiency and Behavioral Disorders.

Condition

Clinical Trials

Trial Phases

Neurological Disorders

13 Actively Recruiting

Not Applicable, Phase 1, Phase 4, Phase 2, Phase 3

Schilling Test

0 Actively Recruiting

prophylaxis of Vitamin B12 deficiency

0 Actively Recruiting

Paralysis

7 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1

Behavior Disorders

0 Actively Recruiting

Anemia, Pernicious

0 Actively Recruiting

Vitamin B complex deficiency

0 Actively Recruiting

Fractures, Multiple

0 Actively Recruiting

Toxic effect of hydrocyanic acid and cyanides

0 Actively Recruiting

Vitamin B 12 Deficiency

0 Actively Recruiting

Iron Deficiency Anemia

20 Actively Recruiting

Phase 3, Not Applicable, Phase 2, Phase 1, Phase 4

Burn Patients

0 Actively Recruiting

Anger Management Therapy

0 Actively Recruiting

Therapeutic Agent Toxicity

2 Actively Recruiting

Phase 2, Phase 1

Hydroxocobalamin Reviews: What are patients saying about Hydroxocobalamin?

4.3

Patient Review

4/23/2013

Hydroxocobalamin for Anemia caused by Vitamin B12 Deficiency-Pernicious Anemia

The hydro b12 injections have really helped me with my PA. I didn't see any improvement with the cyano b12 sublinguals, but the hydro b12 injections have made a huge difference in my thinking, pain levels, and energy levels.

1.7

Patient Review

10/21/2015

Hydroxocobalamin for Anemia caused by Vitamin B12 Deficiency-Pernicious Anemia

After being exposed to mold, I started feeling awful. Extreme fatigue, aching body, brain fog, itchy skin, liver pain and related issues. It was like I had been hit by a baseball bat all over my body! If you're allergic to mold or fungi in any way, stay away from this treatment.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about hydroxocobalamin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What hydroxocobalamin is used for?

"Hydroxocobalamin is a manufactured form of vitamin B12. It is used to treat and prevent vitamin B12 deficiency anaemia, which is when you have low levels of this vitamin in your body."

Answered by AI

How often should hydroxocobalamin be given?

"If a lack of vitamin B12 in your diet is not the cause of your vitamin B12 deficiency, you will likely need to get an injection of hydroxocobalamin every 2 to 3 months for the rest of your life."

Answered by AI

Does hydroxocobalamin contain cyanide?

"Hydroxocobalamin (vitamin B12a) is not universally available, however the older kits still have a role. Hydroxocobalamin has a central cobalt atom that binds cyanide ions, forming cyanocobalamin (vitamin B12), which is nontoxic and renally excreted."

Answered by AI

How do you administer hydroxocobalamin?

"Reveal the upper arm or outer thigh where the injection is to occur. Take off the needle cover. Gently push the needle into the skin until it cannot go any further. Push the plunger down slowly until the syringe is emptied."

Answered by AI

Clinical Trials for Hydroxocobalamin

Image of University Health Network (UHN) in Toronto, Canada.

Mitapivat for Anemia

18+
All Sexes
Toronto, Canada

This is a prospective exploratory phase 2 study designed to evaluate the safety and efficacy of mitapivat in RBC membranopathies and CDAII, a rare sub type of anemia. Nine patients from Princess Margaret who are diagnosed with CDAII will be enrolled to the study. Patients will be in the trial for 57 weeks treatment weeks and a safety follow up week after 30 days from last dose. First 8 weeks will be dose escalating period followed by 48 weeks of fixed dose period. 57th week will be dose tapering week. Data collected from Princes Margaret will be incorporated to the main study conducted in EU for analysis. Overall, approximately 25 patients are expected to be enrolled: Approximately 16 patients at sites in the EU and approximately 9 patients in Canada.

Phase 2
Recruiting

University Health Network (UHN)

Agios Pharmaceuticals, Inc.

Image of University of Rochester Center for Health and Technology (CHeT) in Rochester, United States.

Exercise for Early Parkinson's Disease

18+
All Sexes
Rochester, NY

The goal of this clinical trial is two-fold. First to investigate the feasibility of whether a remotely administered smartphone app can increase the volume and intensity of physical activity in daily life in individuals with a LRRK2 G2019S or GBA1 N370S genetic mutation over a long period of time (24 months). Second, to explore the preliminary efficacy of exercise on markers for prodromal Parkinson's disease progression in individuals with a LRRK2 G2019S or GBA1 N370S genetic mutation. Participants will be tasked to achieve an incremental increase of daily steps (volume) and amount of minutes exercised at a certain heart rate (intensity) with respect to their own baseline level. Motivation with regards to physical activity will entirely be communicated through the study specific Slow Speed smartphone app. A joint primary objective consists of two components. First to determine the longitudinal effect of an exercise intervention in LRRK2 G2019S or GBA1 N370S variant carriers on a prodromal load score, comprised of digital biomarkers of prodromal symptoms. The secondary component of the primary outcome is to determine the feasibility of a remote intervention study. The secondary objective is the effect of a physical activity intervention on digital markers of physical fitness. Exploratory outcomes entail retention rate, completeness of remote digital biomarker assessments, digital prodromal motor and non-motor features of PD. Using these biomarkers, the investigators aim to develop a composite score (prodromal load score) to estimate the total prodromal load. An international exercise study with fellow researchers in the United Kingdom are currently in preparation (Slow-SPEED-UK) and active in the Netherlands (Slow-SPEED-NL). Our intention is to analyse overlapping outcomes combined where possible through a meta-analysis plan, to obtain insight on (determinants of) heterogeneity in compliance and possible efficacy across subgroups

Waitlist Available
Has No Placebo

University of Rochester Center for Health and Technology (CHeT)

Sirwan KL Darweesh, PhD

Hoffmann-La Roche

Have you considered Hydroxocobalamin clinical trials?

We made a collection of clinical trials featuring Hydroxocobalamin, we think they might fit your search criteria.
Go to Trials
Image of University of Minnesota in Minneapolis, United States.

Choline for Iron Deficiency

5 - 7
All Sexes
Minneapolis, MN

BACKGROUND: Iron deficiency limits the neurodevelopmental potential of more than 200 million children each year. Iron therapy is typically started when iron deficiency anemia is first diagnosed after screening for anemia or detection of clinical symptoms of iron deficiency anemia at 12 months of age. But iron started at this time does not fully correct earlier iron-deficiency-mediated brain dysfunction, underscoring the need for low-cost, easily implementable adjunct therapies to iron to treat or prevent this dysfunction in high-risk populations. GAP Supplementation with the nutrient choline lessens damage to the hippocampus from early-life iron deficiency in pre-clinical models and improves hippocampus-mediated memory in children with Fetal Alcohol Spectrum Disorders. Choline has not been tested in children with iron deficiency anemia, despite strong pre-clinical and clinical evidence supporting a benefit to brain development. HYPOTHESIS: Infants with iron deficiency anemia who receive iron and nine months of daily choline supplements will have better scores on specific neurobehavioral tests of recognition memory than infants who receive iron and placebo. METHODS: This randomized, double-blinded, placebo-controlled clinical trial will randomize 300 6-month-old infants with iron deficiency anemia at Mulago Hospital, Kampala, Uganda, to iron plus choline or iron plus placebo to test the effect of choline on hippocampus-specific and global neurobehavioral outcomes after nine months. RESULTS: Pending IMPACT: If our hypothesis is correct, choline could be added immediately to standard-of-care treatment for iron deficiency anemia. This intervention could safely mitigate the brain dysfunction of early-life iron deficiency that is often undiagnosed until the hippocampal critical window is closing. This simple, low-cost nutrient could thus have life-long benefit for both individuals and the economic and social prosperity of entire regions.

Phase 2 & 3
Recruiting

University of Minnesota

Sarah Cusick

Image of University of Pittsburgh in Pittsburgh, United States.

Deep Brain Stimulation for Stroke

18 - 75
All Sexes
Pittsburgh, PA

The goal of this study is to verify whether the use of deep brain stimulation can improve motor function of the hand and arm and speech abilities for people following a stroke. Participants will undergo a surgical procedure to implant deep brain stimulation electrode leads. The electrodes will be connected to external stimulators and a series of experiments will be performed to identify the types of movements that the hand and arm can make and how speech abilities are affected by the stimulation. The implant will be removed after less than 30 days. Results of this study will provide the foundation for future studies evaluating the efficacy of a minimally-invasive neuro-technology that can be used in clinical neuro-rehabilitation programs to restore speech and upper limb motor functions in people with subcortical strokes, thereby increasing independence and quality of life.

Recruiting
Has No Placebo

University of Pittsburgh

Jorge Gonzalez-Martinez, MD/PhD

Image of Columbia University Medical Center in New York, United States.

Iron Supplementation for Scoliosis

10 - 26
All Sexes
New York, NY

This study is a randomized controlled trial of preoperative oral iron supplementation, to identify whether iron deficiency is a modifiable risk factor for adverse surgical outcomes such as red blood cell transfusion and diminished postoperative cognitive and physical capacity in adolescents undergoing scoliosis surgery. Research Question(s)/Hypothesis(es): Primary * Iron supplementation will reduce the incidence of perioperative RBC transfusion in iron deficient scoliosis patients undergoing spinal fusion. Secondary * Iron supplementation will reduce postoperative neurocognitive functional declines in iron deficient scoliosis patients undergoing spinal fusion. * Iron supplementation will improve patient-reported physical functioning in iron deficient scoliosis patients undergoing spinal fusion.

Recruiting
Paid Trial

Columbia University Medical Center

Lisa D Eisler, MD

Have you considered Hydroxocobalamin clinical trials?

We made a collection of clinical trials featuring Hydroxocobalamin, we think they might fit your search criteria.
Go to Trials

Have you considered Hydroxocobalamin clinical trials?

We made a collection of clinical trials featuring Hydroxocobalamin, we think they might fit your search criteria.
Go to Trials